Physician profile
Krishnan Gopal
NPI 1255411716
$2,217.09
in general payments reported to CMS, 2019-2025
29 companies · $17.44 in 2025
The $17.44 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $920 · 2020: $710 · 2021: $405 · 2022: $164 · 2025: $17.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $498.81 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $252.13 | 2019-2022 | |
| Genentech USA, INC. | $194.45 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.83 | 2022 | |
| Janssen Biotech, INC. | $103.40 | 2019-2021 | |
| Genzyme Corporation | $102.86 | 2019-2021 | |
| Amgen INC. | $97.86 | 2020-2021 | |
| Lilly USA, LLC | $92.40 | 2019-2020 | |
| Pfizer INC. | $68.31 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $67.99 | 2019-2025 | |
| Eisai INC. | $66.20 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $62.52 | 2019-2020 | |
| Celgene Corporation | $53.84 | 2019-2020 | |
| Seagen INC. | $53.79 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.50 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $48.65 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $44.28 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.34 | 2019 | |
| Kite Pharma, INC. | $33.82 | 2020 | |
| Incyte Corporation | $26.35 | 2019-2020 | |
| Abbvie INC. | $24.76 | 2019-2020 | |
| Myovant Sciences INC. | $14.70 | 2021 | |
| Tesaro, INC. | $14.52 | 2019 | |
| Kyowa Kirin, INC. | $13.93 | 2021 | |
| Eusa Pharma (US) LLC | $13.64 | 2019 | |
| Daiichi Sankyo INC. | $13.42 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.19 | 2020 | |
| Gilead Sciences, INC. | $12.46 | 2019 | |
| Array Biopharma INC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krishnan Gopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.